Addario Lung Cancer Medical Institute
14
1
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
35.7%
5 terminated/withdrawn out of 14 trials
37.5%
-49.0% vs industry average
0%
0 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Immune and Genomic Markers in ALK+ NSCLC
Role: collaborator
Studying Pathways of Resistance in KRAS-driven Cancers
Role: lead
Epidemiology of Young Lung Cancer - Survey
Role: lead
INHERIT EGFR - Studying Germline EGFR Mutations
Role: collaborator
Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance
Role: lead
A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)
Role: lead
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
Role: lead
Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy
Role: lead
Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer
Role: collaborator
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
Role: lead
ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors
Role: lead
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Role: lead
PDX Models From EGFR Mutant Tumors
Role: lead
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
Role: collaborator
All 14 trials loaded